Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study
European Journal of Cancer · 2024-06 · 204 · 114071
DOI: 10.1016/j.ejca.2024.114071 ↗Kurz gefasst
Fallbericht in der Zeitschrift European Journal of Cancer, 2024-06. Verfasst von Marion Subklewe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Laboratory for Translational Cancer Immunolog…. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Scleroderma, Systemic, Antigens, CD19. Die Arbeit wurde bisher 97-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: European Union, Deutsche Forschungsgemeinschaft.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany; Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany; German Cancer Consortium (DKTK),…
- Department of Medicine III - Hematology/Oncology, LMU University Hospital, LMU Munich, Munich, Germany. Electronic address: Giulia.Magno@med.uni-muenchen.de.
- Division of Rheumatology and Clinical Immunology, Department of Medicine IV, LMU University Hospital, LMU Munich, Munich, Germany. Electronic address: Christina.Gebhardt@med.uni-muenchen.de.
- Department of Medicine, Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany. Electronic address: Franziska.Szelinski@charite.de.
- Department of Medicine, Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany. Electronic address: Hector.Rincon@charite.de.
- Laboratory for Translational Cancer Immunology, LMU Gene Center, Munich, Germany. Electronic address: haenel@genzentrum.lmu.de.
Förderung
- European Union
- Deutsche Forschungsgemeinschaft
Zitieren
APA
Subklewe, M., Magno, G., Gebhardt, C., Bücklein, V., Szelinski, F., Arévalo, H. J. R., Hänel, G., Dörner, T., Zugmaier, G., von Bergwelt-Baildon, M., Skapenko, A., & Schulze-Koops, H. (2024). Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study. European Journal of Cancer, 204, 114071. https://doi.org/10.1016/j.ejca.2024.114071
Vancouver
Subklewe M, Magno G, Gebhardt C, Bücklein V, Szelinski F, Arévalo HJR, et al. Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study. European Journal of Cancer. 2024;204:114071. doi:10.1016/j.ejca.2024.114071
BibTeX
@article{Subklewe2024,
author = {Subklewe, Marion and Magno, Giulia and Gebhardt, Christina and Bücklein, Veit and Szelinski, Franziska and Arévalo, Héctor Julián Rincón and Hänel, Gerulf and Dörner, Thomas and Zugmaier, Gerhard and von Bergwelt-Baildon, Michael and Skapenko, Alla and Schulze-Koops, Hendrik},
title = {Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study},
journal = {European Journal of Cancer},
year = {2024},
volume = {204},
pages = {114071},
doi = {10.1016/j.ejca.2024.114071}
}
EUVIMED